by The global Rat And Mouse Model market size is expected to be worth around US$ 6.9 billion by 2030, according to a new report by Vision Research Reports.
The global Rat And Mouse Model market size was valued at US$ 2.9 billion in 2020 and is anticipated to grow at a CAGR of 6.5% during forecast period 2021 to 2030.
Download Exclusive Sample of Report@ https://www.visionresearchreports.com/report/sample/38979
Table of Contents
Rat And Mouse Model Market Growth Factors
The growth of this market is majorly driven by the increasing demand for genetically modified models to help researchers identify and validate therapeutic targets. Additionally, increasing expenditures in R&D activities in the pharmaceutical and biotechnology sector is likely to fuel market growth.
The growth of personalized medicine boosts the demand for humanized rat and mouse models across the globe. Charles River Laboratories offers custom rare disease and microbiome models that support personalized therapy drug trials. The growing need for primary tissue/cells and human-like animal models propel the demand for customized models to assess safety, efficacy, and target validation in cellular therapies.
Rat And Mouse Model Market Report Coverage
| Report Scope | Details |
| Market Size | US$ 6.9 Billion by 2030 |
| Growth Rate | CAGR of 6.5% From 2021 to 2030 |
| Base Year | 2021 |
| Forecast Period | 2021 to 2030 |
| Segments Covered | Type, Technology, Service, Application, End-use |
| Regional Scope | North America, Europe, Asia Pacific, Latin America, Middle East & Africa |
| Companies Mentioned | Charles River Laboratories International, Inc.; The Jackson Laboratory; Laboratory Corporation of America Holdings (Covance); Perkin Elmer (Horizon Discovery Group plc); genOway; Envigo; JANVIER LABS; Taconic Biosciences Inc.; Biomedical Research Models (Biomere); Transpogen Biopharmaceutical, Inc |
By Type Analysis
The outbred segment dominated the market for rat and mouse model and accounted for the largest revenue share of 22.6% in 2020. These models accurately represent the genomic structure of humans and hence are employed in research involving human subjects.
Inbred strains accounted for the second-largest revenue share of the market owing to the advantages offered by them in disease research. These models are economical, readily available, homogenous, and are genetically stable.
The knock-in segment is expected to witness the fastest CAGR in the market for rat and mouse model over the forecast period as they can be used to determine the effects of minute changes in the function and structure of proteins.
By Technology Analysis
Based on technology, the CRISPR/Cas9 technology segment dominated the market for rat and mouse model and accounted for the largest revenue share of 22.4% in 2020.
The use of CRISPR knock-in and knock-out rodent models in research involving human diseases has shown promising results. For instance, the application of CRISPR/CAS 9 to edit the β-globin gene has successfully enhanced the level of fetal hemoglobin for the treatment of sickle-cell diseases in mice.
By Service Analysis
Based on the services, the breeding segment dominated the market for rat and mouse model and accounted for the largest revenue share of 31.4% in 2020. This is attributed to the increasing demand for rat and mouse models for the development and drug discovery and subsequent increase in the demand for personalized medicines.
The cryopreservation segment is expected to witness the fastest CAGR throughout the forecast period. Cryopreservation of embryo and sperm from rat and mouse models creates a cost-efficient backup of live animal colonies which do not have many applications in the present scenario but may prove to be extremely useful in the future.
Cryoservices offered by key companies, such as Charles River Laboratories, help in the protection of animal lines in case of natural disaster, a catastrophic accident, microbial contamination, and alteration of gene expression in later generations.
By Application Analysis
The cancer segment dominated the market for rat and mouse model and accounted for the largest revenue share of 17.9% in 2020. Rat and mice models provide various aspects of progression, genesis, and clinical course of human cancers.
With the successful development and implementation of mRNA vaccines for COVID-19, their makers are now exploring ways to use mRNA therapies for other diseases including cancer.
A rise in initiatives to utilize rodent models for cancer drug development is expected to increase the revenue generation in this segment.
By End-use Analysis
The pharmaceutical and biotechnology companies segment held the largest revenue share of 41.9% in 2020. Increasing applications of the rat and mice model in the production of vaccines for infectious diseases are expected to boost the segment further during the forecast period.
The development of mouse models that can generate a human version of ACE2 has increased their adoption rate in the pharmaceutical and biotechnology companies for COVID-19 research.
By Regional Analysis
North America dominated the rat and mouse model market and accounted for the highest revenue share of 49.8% in 2020. This is attributed to the presence of key market players and the growth in pharmaceutical as well as research sectors in this region.
Europe held the second-largest market share owing to the rise in research activities involving the use of rodent models. The researchers have also successfully tested gene therapy which cures alterations of the whole body observed in rat models with Morquio A disease.
Read also @ Hospital Consumables Market is Anticipated to Grow US$ 813.1 Billion By 2030
Major Key Players Covered in The Rat And Mouse Model Market Report include
- Charles River Laboratories International, Inc.
- The Jackson Laboratory
- Laboratory Corporation of America Holdings (Covance)
- Perkin Elmer (Horizon Discovery Group plc)
- genOway
- Envigo
- JANVIER LABS
- Taconic Biosciences, Inc.
- Biomedical Research Models (Biomere)
- Transpogen Biopharmaceutical, Inc.
Rat And Mouse Model Market Segmentation
- By Type
- Knockout
- Knock-in
- Outbred
- Inbred
- Others
- By Technology
- Nuclear transferase
- Microinjection
- Embryonic stem cells
- CRISPR/Cas9
- Others
- By Service
- Cryopreservation
- Breeding
- Rederivation
- Genetic testing
- Quarantine depending
- Others
- By Application
- Cardiovascular diseases
- Genetic diseases
- Cancer
- Infectious diseases
- COVID-19
- Others
- Transplantation
- Toxicology studies
- Others
- By End-use
- Pharmaceutical companies
- Academic and research facilities
- Biotechnology companies
- Contract research & manufacturing organizations
- Regional
- North America
- U.S.
- Canada
- Europe
- Germany
- France
- U.K.
- Italy
- Spain
- Asia Pacific
- China
- Japan
- India
- Latin America
- Brazil
- Mexico
- MEA
- South Africa
- Saudi Arabia
- North America
Table of Contents
Chapter 1. Introduction
1.1. Research Objective
1.2. Scope of the Study
1.3. Definition
Chapter 2. Research Methodology
2.1. Research Approach
2.2. Data Sources
2.3. Assumptions & Limitations
Chapter 3. Executive Summary
3.1. Rat And Mouse Model Market Snapshot
Chapter 4. Rat And Mouse Model Market Variables and Scope
4.1. Introduction
4.2. Rat And Mouse Model Market Classification and Scope
4.3. Industry Value Chain Analysis
4.3.1. Raw Material Procurement Analysis
4.3.2. Sales and Distribution Channel Analysis
4.3.3. Downstream Buyer Analysis
Chapter 5. Rat And Mouse Model Market Dynamics Analysis and Trends
5.1. Rat And Mouse Model Market Dynamics
5.1.1. Rat And Mouse Model Market Drivers
5.1.2. Rat And Mouse Model Market Restraints
5.1.3. Rat And Mouse Model Market Opportunities
5.2. Porter’s Five Forces Analysis
5.2.1. Bargaining power of suppliers
5.2.2. Bargaining power of buyers
5.2.3. Threat of substitute
5.2.4. Threat of new entrants
5.2.5. Degree of competition
Chapter 6. Competitive Landscape
6.1.1. Company Market Share/Positioning Analysis
6.1.2. Key Strategies Adopted by Players
6.1.3. Vendor Landscape
6.1.3.1. List of Suppliers
6.1.3.2. List of Buyers
Chapter 7. Global Rat And Mouse Model Market, By Type
7.1. Rat And Mouse Model Market, by Type, 2021-2030
7.1.1. Knockout
7.1.1.1. Market Revenue and Forecast (2017-2030)
7.1.2. Knock-in
7.1.2.1. Market Revenue and Forecast (2017-2030)
7.1.3. Outbred
7.1.3.1. Market Revenue and Forecast (2017-2030)
7.1.4. Inbred
7.1.4.1. Market Revenue and Forecast (2017-2030)
Chapter 8. Global Rat And Mouse Model Market, By Technology
8.1. Rat And Mouse Model Market, by Technology, 2021-2030
8.1.1. Nuclear transferase
8.1.1.1. Market Revenue and Forecast (2017-2030)
8.1.2. Microinjection
8.1.2.1. Market Revenue and Forecast (2017-2030)
8.1.3. Embryonic stem cells
8.1.3.1. Market Revenue and Forecast (2017-2030)
8.1.4. CRISPR/Cas9
8.1.4.1. Market Revenue and Forecast (2017-2030)
Chapter 9. Global Rat And Mouse Model Market, By Service
9.1. Rat And Mouse Model Market, by Service, 2021-2030
9.1.1. Cryopreservation
9.1.1.1. Market Revenue and Forecast (2017-2030)
9.1.2. Breeding
9.1.2.1. Market Revenue and Forecast (2017-2030)
9.1.3. Rederivation
9.1.3.1. Market Revenue and Forecast (2017-2030)
9.1.4. Genetic testing
9.1.4.1. Market Revenue and Forecast (2017-2030)
9.1.5. Quarantine depending
9.1.5.1. Market Revenue and Forecast (2017-2030)
Chapter 10. Global Rat And Mouse Model Market, By Application
10.1. Rat And Mouse Model Market, by Application, 2021-2030
10.1.1. Cardiovascular diseases
10.1.1.1. Market Revenue and Forecast (2017-2030)
10.1.2. Genetic diseases
10.1.2.1. Market Revenue and Forecast (2017-2030)
10.1.3. Cancer
10.1.3.1. Market Revenue and Forecast (2017-2030)
10.1.4. Infectious diseases
10.1.4.1. Market Revenue and Forecast (2017-2030)
10.1.5. Transplantation
10.1.5.1. Market Revenue and Forecast (2017-2030)
10.1.6. Toxicology studies
10.1.6.1. Market Revenue and Forecast (2017-2030)
Chapter 11. Global Rat And Mouse Model Market, By End-use
11.1. Rat And Mouse Model Market, by End-use, 2021-2030
11.1.1. Pharmaceutical companies
11.1.1.1. Market Revenue and Forecast (2017-2030)
11.1.2. Academic and research facilities
11.1.2.1. Market Revenue and Forecast (2017-2030)
11.1.3. Biotechnology companies
11.1.3.1. Market Revenue and Forecast (2017-2030)
11.1.4. Contract research & manufacturing organizations
11.1.4.1. Market Revenue and Forecast (2017-2030)
Chapter 12. Global Rat And Mouse Model Market, Regional Estimates and Trend Forecast
12.1. North America
12.1.1. Market Revenue and Forecast, by Type (2017-2030)
12.1.2. Market Revenue and Forecast, by Technology (2017-2030)
12.1.3. Market Revenue and Forecast, by Service (2017-2030)
12.1.4. Market Revenue and Forecast, by Application (2017-2030)
12.1.5. Market Revenue and Forecast, by End-use (2017-2030)
12.1.6. U.S.
12.1.6.1. Market Revenue and Forecast, by Type (2017-2030)
12.1.6.2. Market Revenue and Forecast, by Technology (2017-2030)
12.1.6.3. Market Revenue and Forecast, by Service (2017-2030)
12.1.6.4. Market Revenue and Forecast, by Application (2017-2030)
12.1.6.5. Market Revenue and Forecast, by End-use (2017-2030)
12.1.7. Rest of North America
12.1.7.1. Market Revenue and Forecast, by Type (2017-2030)
12.1.7.2. Market Revenue and Forecast, by Technology (2017-2030)
12.1.7.3. Market Revenue and Forecast, by Service (2017-2030)
12.1.7.4. Market Revenue and Forecast, by Application (2017-2030)
12.1.7.5. Market Revenue and Forecast, by End-use (2017-2030)
12.2. Europe
12.2.1. Market Revenue and Forecast, by Type (2017-2030)
12.2.2. Market Revenue and Forecast, by Technology (2017-2030)
12.2.3. Market Revenue and Forecast, by Service (2017-2030)
12.2.4. Market Revenue and Forecast, by Application (2017-2030)
12.2.5. Market Revenue and Forecast, by End-use (2017-2030)
12.2.6. UK
12.2.6.1. Market Revenue and Forecast, by Type (2017-2030)
12.2.6.2. Market Revenue and Forecast, by Technology (2017-2030)
12.2.6.3. Market Revenue and Forecast, by Service (2017-2030)
12.2.6.4. Market Revenue and Forecast, by Application (2017-2030)
12.2.6.5. Market Revenue and Forecast, by End-use (2017-2030)
12.2.7. Germany
12.2.7.1. Market Revenue and Forecast, by Type (2017-2030)
12.2.7.2. Market Revenue and Forecast, by Technology (2017-2030)
12.2.7.3. Market Revenue and Forecast, by Service (2017-2030)
12.2.7.4. Market Revenue and Forecast, by Application (2017-2030)
12.2.7.5. Market Revenue and Forecast, by End-use (2017-2030)
12.2.8. France
12.2.8.1. Market Revenue and Forecast, by Type (2017-2030)
12.2.8.2. Market Revenue and Forecast, by Technology (2017-2030)
12.2.8.3. Market Revenue and Forecast, by Service (2017-2030)
12.2.8.4. Market Revenue and Forecast, by Application (2017-2030)
12.2.8.5. Market Revenue and Forecast, by End-use (2017-2030)
12.2.9. Rest of Europe
12.2.9.1. Market Revenue and Forecast, by Type (2017-2030)
12.2.9.2. Market Revenue and Forecast, by Technology (2017-2030)
12.2.9.3. Market Revenue and Forecast, by Service (2017-2030)
12.2.9.4. Market Revenue and Forecast, by Application (2017-2030)
12.2.9.5. Market Revenue and Forecast, by End-use (2017-2030)
12.3. APAC
12.3.1. Market Revenue and Forecast, by Type (2017-2030)
12.3.2. Market Revenue and Forecast, by Technology (2017-2030)
12.3.3. Market Revenue and Forecast, by Service (2017-2030)
12.3.4. Market Revenue and Forecast, by Application (2017-2030)
12.3.5. Market Revenue and Forecast, by End-use (2017-2030)
12.3.6. India
12.3.6.1. Market Revenue and Forecast, by Type (2017-2030)
12.3.6.2. Market Revenue and Forecast, by Technology (2017-2030)
12.3.6.3. Market Revenue and Forecast, by Service (2017-2030)
12.3.6.4. Market Revenue and Forecast, by Application (2017-2030)
12.3.6.5. Market Revenue and Forecast, by End-use (2017-2030)
12.3.7. China
12.3.7.1. Market Revenue and Forecast, by Type (2017-2030)
12.3.7.2. Market Revenue and Forecast, by Technology (2017-2030)
12.3.7.3. Market Revenue and Forecast, by Service (2017-2030)
12.3.7.4. Market Revenue and Forecast, by Application (2017-2030)
12.3.7.5. Market Revenue and Forecast, by End-use (2017-2030)
12.3.8. Japan
12.3.8.1. Market Revenue and Forecast, by Type (2017-2030)
12.3.8.2. Market Revenue and Forecast, by Technology (2017-2030)
12.3.8.3. Market Revenue and Forecast, by Service (2017-2030)
12.3.8.4. Market Revenue and Forecast, by Application (2017-2030)
12.3.8.5. Market Revenue and Forecast, by End-use (2017-2030)
12.3.9. Rest of APAC
12.3.9.1. Market Revenue and Forecast, by Type (2017-2030)
12.3.9.2. Market Revenue and Forecast, by Technology (2017-2030)
12.3.9.3. Market Revenue and Forecast, by Service (2017-2030)
12.3.9.4. Market Revenue and Forecast, by Application (2017-2030)
12.3.9.5. Market Revenue and Forecast, by End-use (2017-2030)
12.4. MEA
12.4.1. Market Revenue and Forecast, by Type (2017-2030)
12.4.2. Market Revenue and Forecast, by Technology (2017-2030)
12.4.3. Market Revenue and Forecast, by Service (2017-2030)
12.4.4. Market Revenue and Forecast, by Application (2017-2030)
12.4.5. Market Revenue and Forecast, by End-use (2017-2030)
12.4.6. GCC
12.4.6.1. Market Revenue and Forecast, by Type (2017-2030)
12.4.6.2. Market Revenue and Forecast, by Technology (2017-2030)
12.4.6.3. Market Revenue and Forecast, by Service (2017-2030)
12.4.6.4. Market Revenue and Forecast, by Application (2017-2030)
12.4.6.5. Market Revenue and Forecast, by End-use (2017-2030)
12.4.7. North Africa
12.4.7.1. Market Revenue and Forecast, by Type (2017-2030)
12.4.7.2. Market Revenue and Forecast, by Technology (2017-2030)
12.4.7.3. Market Revenue and Forecast, by Service (2017-2030)
12.4.7.4. Market Revenue and Forecast, by Application (2017-2030)
12.4.7.5. Market Revenue and Forecast, by End-use (2017-2030)
12.4.8. South Africa
12.4.8.1. Market Revenue and Forecast, by Type (2017-2030)
12.4.8.2. Market Revenue and Forecast, by Technology (2017-2030)
12.4.8.3. Market Revenue and Forecast, by Service (2017-2030)
12.4.8.4. Market Revenue and Forecast, by Application (2017-2030)
12.4.8.5. Market Revenue and Forecast, by End-use (2017-2030)
12.4.9. Rest of MEA
12.4.9.1. Market Revenue and Forecast, by Type (2017-2030)
12.4.9.2. Market Revenue and Forecast, by Technology (2017-2030)
12.4.9.3. Market Revenue and Forecast, by Service (2017-2030)
12.4.9.4. Market Revenue and Forecast, by Application (2017-2030)
12.4.9.5. Market Revenue and Forecast, by End-use (2017-2030)
12.5. Latin America
12.5.1. Market Revenue and Forecast, by Type (2017-2030)
12.5.2. Market Revenue and Forecast, by Technology (2017-2030)
12.5.3. Market Revenue and Forecast, by Service (2017-2030)
12.5.4. Market Revenue and Forecast, by Application (2017-2030)
12.5.5. Market Revenue and Forecast, by End-use (2017-2030)
12.5.6. Brazil
12.5.6.1. Market Revenue and Forecast, by Type (2017-2030)
12.5.6.2. Market Revenue and Forecast, by Technology (2017-2030)
12.5.6.3. Market Revenue and Forecast, by Service (2017-2030)
12.5.6.4. Market Revenue and Forecast, by Application (2017-2030)
12.5.6.5. Market Revenue and Forecast, by End-use (2017-2030)
12.5.7. Rest of LATAM
12.5.7.1. Market Revenue and Forecast, by Type (2017-2030)
12.5.7.2. Market Revenue and Forecast, by Technology (2017-2030)
12.5.7.3. Market Revenue and Forecast, by Service (2017-2030)
12.5.7.4. Market Revenue and Forecast, by Application (2017-2030)
12.5.7.5. Market Revenue and Forecast, by End-use (2017-2030)
Chapter 13. Company Profiles
13.1. Charles River Laboratories International, Inc.
13.1.1. Company Overview
13.1.2. Product Offerings
13.1.3. Financial Performance
13.1.4. Recent Initiatives
13.2. The Jackson Laboratory
13.2.1. Company Overview
13.2.2. Product Offerings
13.2.3. Financial Performance
13.2.4. Recent Initiatives
13.3. Laboratory Corporation of America Holdings (Covance)
13.3.1. Company Overview
13.3.2. Product Offerings
13.3.3. Financial Performance
13.3.4. Recent Initiatives
13.4. Perkin Elmer (Horizon Discovery Group plc)
13.4.1. Company Overview
13.4.2. Product Offerings
13.4.3. Financial Performance
13.4.4. Recent Initiatives
13.5. genOway
13.5.1. Company Overview
13.5.2. Product Offerings
13.5.3. Financial Performance
13.5.4. Recent Initiatives
13.6. Envigo
13.6.1. Company Overview
13.6.2. Product Offerings
13.6.3. Financial Performance
13.6.4. Recent Initiatives
13.7. JANVIER LABS
13.7.1. Company Overview
13.7.2. Product Offerings
13.7.3. Financial Performance
13.7.4. Recent Initiatives
13.8. Taconic Biosciences, Inc.
13.8.1. Company Overview
13.8.2. Product Offerings
13.8.3. Financial Performance
13.8.4. Recent Initiatives
13.9. Biomedical Research Models (Biomere)
13.9.1. Company Overview
13.9.2. Product Offerings
13.9.3. Financial Performance
13.9.4. Recent Initiatives
13.10. Transpogen Biopharmaceutical, Inc.
13.10.1. Company Overview
13.10.2. Product Offerings
13.10.3. Financial Performance
13.10.4. Recent Initiatives
Chapter 14. Research Methodology
14.1. Primary Research
14.2. Secondary Research
14.3. Assumptions
Chapter 15. Appendix
15.1. About Us
15.2. Glossary of Terms
Buy this Research Report study@ https://www.visionresearchreports.com/report/cart/38979
Contact Us:
Vision Research Reports
Call: +1 9197 992 333
